Intranasal photobiomodulation (iPBM) is a distinct form of application of photobiomodulation. In itself, photobiomodulation (PBM) is a relatively new field. Even the word itself is quite new. It is familiar to mostly a limited group of scientists, engineers, early adopters and health practitioners. However, the applications and effects of PBM are gathering more interest and attention from the scientific and medical communities. Over the last 2-3 years this interest has become stronger, as new research has delivered more supportive evidence.

At this time the research specific to iPBM is limited, and it is no surprise, considering how novel this method is. Nevertheless, some studies point to strong possibilities that intranasal photobiomodulation can support and strengthen immune system via mitochondrial and cellular functions. Importantly, potential applications for intranasal PBM can be numerous, and already research studies are planned in search of more evidence.

As it is often the case with any new technology, it attracts more skepticism than support in its early days. This is a normal course of development for most novelties. History has plenty of examples of misunderstandings directed at important inventions, from cars and airplanes to, more recently, the Internet. The common misunderstanding was to consider those inventions temporary fads. Intranasal photobiomodulation is likely the newest form of PBM, and as such it gathers healthy doses of interest and skepticism.

Is there evidence supporting intranasal photobiomodulation’s effectiveness?

The only way to win the skeptics over is to provide strong evidence in support of intranasal photobiomodulation’s effectiveness. Luckily, a body of such supporting evidence is growing, as more scientists are taking closer looks at PBM.

This momentum-gaining is happening mainly due to four critical factors associated with PBM in general. Factor one is the success of exploratory studies, resulting in robust scientific validation of the PBM method for numerous applications. Factor two is the noninvasive nature of this modality. Simplicity of PBM delivery is factor three. Last, but not least, factor four is cost-effectiveness of the PBM procedures.

However, no matter how attractive PBM may look to researchers, most regulatory bodies require solid data to permit medical use. Intranasal photobiomodulation is no exception. While numerous studies create a generally positive and promising picture of PBM for many applications, these studies present a somewhat fragmented view. Yet, fragmentation, although challenging, is a common starting point to solving any puzzle.

Any reasonable solution would require a creative approach to organizing existing data from numerous photobiomodulation studies into meaningful metrics. Subsequently, when all known pieces are put together, it is much easier to understand what is missing. This approach would allow development of a methodical search for the missing data, which could support medical applications for PBM. Opportunities for such applications are numerous, and those include intranasal photobiomodulation applications.

What prospects for intranasal photobiomodulation does data show?

What about the analytical approach to scientific research in PBM and iPBM? For example, is it important to look at all the data in order to connect the dots for applications of intranasal photobiomodulaton? If you are interested in the future of PBM as a clinical therapy, you may be curious about the answers.

What does photobiomodulation research have to do with detective’s work?

Every once in a while you are likely to catch yourself making an inference based on partial facts, fragmented data, or observations which are not sufficient for a clear-cut conclusion. In some cases a deductive reasoning approach can be very effective. After all, this is what most detectives do. Remember the infamous Mr. Sherlock Holmes and his incredible deductive method and abilities?

Actually, more often than not, intelligence and counterintelligence analysts have to use partial data to understand and complete a puzzle. Research is a lot like the work of detectives and analysts, and similarities in approach are warranted. In general, most analysts use extrapolations and statistics in their analyses. It is reasonable to assume that oftentimes many of such deductions lead to correct conclusions and proofs. Otherwise, analytical deductions would not be an accepted practice.

Photobiomodulation and its applications should not be any different, when it comes to connecting the dots to find missing pieces. Thus, the theory of probabilities can be helpful in solving some convoluted puzzles and offering keys to finding better answers. Whatever the path to finding the right answers may be, the most important part is to find an undeniable validation. Ultimately, such validation will be based on solid scientific data, even if the intermittent research utilized deductions and creative guessing.

Experimental design approach and intranasal photobiomodulation

Experimental design is another practical area where partial data can lead to useful conclusions. Practice of experimental design can provide valuable insights and solutions relevant to intranasal photobiomodulation and PBM in general. The concept of experimental design is used in many industries and for numerous applications, including scientific research.
For example, many scientific studies employ experimental design principles to prove a “concept”, or rather a hypothesis. In addition to complying with regulatory requirements and various standards, researchers have the flexibility to test their hypotheses. Thus, they can manipulate different variables in a study, to achieve and observe changes in the outcomes. This is a form of experimental design in practice.

However, in scientific research, the number of variables can be dramatically high. This fact limits the possibility to test all variations in outcomes. Consequently, in such cases, researchers would have to base their conclusions on the data derived from limited samples. Therefore, they would have to resort to extrapolation based on the sampled data. Thus, the quality and integrity of the sampled data is of critical importance in making correct conclusions.

PBM and iPBM have promising future

This all may sound too scientific for some of you and not enough so for others. Whatever category you are in, you are most likely have some interest in PBM. The important part is that a lot of work is being done to investigate photobiomodulation effects on the human brain and on the body’s systemic functions. In investigations of the former, primarily transcranial photobiomodulation devices emitting near infrared light are used. For investigations of the latter, the red-light emitting intranasal photobiomodulation devices may be of better use. However, in many cases, combinations of both provide promising outcomes and warrant more investigations to gain valuable data.

The more valid scientific data is available, the faster we will answer the numerous PBM-related questions. With science on the side of PBM, the range of its applications to improve human body functions will expand.

The post What about Intranasal Photobiomodulation’s Effectiveness and Research? first appeared on Vielight Inc - Deutsch.

The post What about Intranasal Photobiomodulation’s Effectiveness and Research? appeared first on Vielight Inc - Deutsch.

The Alzheimer’s Association International Conference (AAIC) is the largest annual conference for Alzheimer’s Disease. This year, it takes place in Los Angeles, California, from July 12 to 18, 2019. Vielight will have a presence in this year’s conference. This year is particularly important in view of the commencement of its pivotal clinical trial in late May of 2019.

Presently there is no effective treatment for the Alzheimer’s Disease (AD). All major drug trials in final phases have failed to show any modification to the disease. There is no new final-phase drug trial in prospect for the next year. Late stage trials normally take a few years to complete. There is certainly none, in the near future, with a focus on patients diagnosed to be in the moderate to severe stages of AD.

In the Vielight pivotal clinical trial, the “Vielight Neuro RX Gamma” is being investigated as a possible indication for patients with moderate to severe stages of AD. This ignored group is in a great need of help for recovery, or at least for slowing down in their decline. No other device is known to be actively investigated as a treatment for the AD at this time. These circumstances should spotlight the efforts of Vielight. The initial case studies have shown some unprecedented positive outcomes. The noteworthy published studies include Saltmarche et al, 2017 and Chao, L, 2019.

Presentation and Poster on Photobiomodultaion Research

At the AAIC, Vielight will have a booth (#221) to showcase the device being used in the clinical trial. Furthermore, its lineup of other low-risk, general wellness PBM devices will be on display. Attendees will have an opportunity to have hands-on experience with the device used in the clinical trial, as well as the other Vielight devices.
Dr. Lew Lim, CEO of Vielight, will be presenting evidence of the Neuro Gamma modulating brain wave oscillations and connectivity. This presentation will be a part of the pre-conference program, Electrophysiology Professional Interest Area (PIA) Day. It will take place at 9.30 am on Saturday, July 13, at the Intercontinental Los Angeles Downtown Hotel. The presentation will include information on how these neuro-modifications can affect Alzheimer’s disease.

Dr. Lim will also be presenting a poster, “Photobiomodulation Presents Early Evidence of Significant Outcomes for Alzheimer’s Disease, Enhanced with Multi-Dimensional Interventions”. The poster presentation will take place as # P1-067 on Sunday, July 14, 2019, between 9:30 AM and 4:15 PM at the Los Angeles Convention Center, South Hall GH. The abstract for the poster can be found by following this link.

Participation at the AAIC is the latest event in Vielight’s quest for an effective treatment for Alzheimer’s Disease. We will continue to keep our supporters and followers abreast of further developments.

Vielight to Research the Mechanisms of Photobiomodulation

Vielight has always been committed to furthering the science of Photobiomodulation (PBM). This time Vielight is planning to commence research into furthering the understanding of the mechanisms of PBM.

CEO, Dr. Lim states:

“For many years, the explanation for the mechanisms of PBM has been centered around the actions of the respiratory chain of the mitochondria, and the follow-through actions of gene transcriptions. However, the big question of how penetration and deep-lying outcomes have been achieved with low-power/dose of red and near infrared light craves for an answer. In transcranial PBM, we have proven that certain non-invasive parameters can modify brain waves and connectivity in significant ways. Nonetheless, how cellular actions can translate into high-level brain modulations remains a major mystery.

I have always believed that the photons, as quantum particles, have unique and powerful properties that could penetrate deeply and be more effective on modifying tissues. Discoveries in quantum biology relating to photosynthesis are providing many clues. I believe that we have to include quantum physics into PBM research to help us answer many questions. Quantum physics may also help in better formulating theories for us to be more efficient in developing better products. In the near future, we hope to announce collaborative research initiatives with top scientists in the field in the quest for answers.”

Photobiomodulation Presents Early Evidence of Significant Outcomes for Alzheimer’s Disease, Enhanced with Multi-Dimensional Interventions

Poster Abstract:

Background: Alzheimer’s Disease (AD) has a complex etiology, involving the actions of genes, beta-amyloid, tau oligomers, as well as other possible causes including herpes virus, micro-biome or diabetes. Because of this, the search for a single-protein targeting drug solution could be futile. Over the years, research on Photobiomodulation (PBM) indicates that although it is a single intervention, it has multiple pathways that potentially lead to effectively address AD. This review shows evidence that adding gamma-pulsing and network targeting dimensions, the outcomes could be more significant.

Method:

This is a review of relevant published as well publication-pending literature at the time of writing.

Result:

Restoring optimum mitochondrial function could help to overcome the complex pathology of AD, including the elements that involve beta-amyloid and tau-related aggregations. PBM at its basic dimension activates mitochondrial functions to restore homeostasis, which process could reduce these elements. The process modifies various proteins for favorable gene transcriptions. Introducing another dimension in intervention, by delivering 40 Hz pulses (gamma oscillations), theoretically reduces beta-amyloid accumulation in the processing nuclei. Intervening in yet another dimension, targeting the default mode network could reduce lesions in critical areas and help to restore normal brain functions.

These multi-dimensional mechanisms have been reflected in clinical evidence showing significant outcomes in early exploratory controlled studies. Clinical cognitive assessments from ADAS-cog and MMSE are supported by fMRI and EEG measures. Pre and post single 20-minute sessions of 40 Hz pulsing have even revealed acute changes in EEG power spectrum and connectivity with properties desirable to reverse AD pathology. Recent discoveries reveal that although PBM has shown potential as an AD intervention, enhanced outcomes are possible with attention to pulse-frequency and anatomical-targeting.

Conclusion:

PBM have been under-appreciated as a promising intervention for AD. Early clinical evidence reveals its potential, and it is clear that large randomized controlled studies are warranted. This review aggregates the understanding of the fundamental mechanisms, higher-level network and brain oscillation properties. It helps to provide a better appreciation of PBM potential for AD. The multi-dimensional mechanisms explain why it could be more promising than mono-targeting, characteristic of drug development.

Vielight is Growing

We welcome Haley Dwyer into our customer service team.

The post Photobiomodulation Research Continues first appeared on Vielight Inc - Deutsch.

The post Photobiomodulation Research Continues appeared first on Vielight Inc - Deutsch.